Altimmune, Inc. · NASDAQ:ALT
Altimmune — Pharmathene — Bio Investor Forum San Francisco 2013
23 slides from Altimmune's conference presentation, Oct 8, 2013
Slide 1: Turning the Human Repertoire's Most Potent Antibodies into Superior Therapeutics
Turning the Human Repertoire’s Most Potent Antibodies into Superior Therapeutics Bio Investor Forum San Francisco October 8, 2013 Clifford J. Stocks Chief Executive Officer
Slide 2: Theraclone / PharmAthene
2 Theraclone / PharmAthene Theraclone Sciences, Inc., a monoclonal antibody discovery and development company , and PharmAthene , Inc., (NYSE MKT: PIP) a leading biodefense company, announced an intention to merge to form a commercially - focused biologics company with extensive vaccines and therape
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement Except for the historical information presented herein, matters discussed may constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results
Slide 4: Important Additional Information About the Merger
4 Important Additional Information About the Merger This communication is being made in respect of the proposed merger involving Theraclone Sciences, Inc. (“Theraclone”) and PharmAthene. On August 1, 2013, PharmAthene filed with the SEC a current report on Form 8 - K, which includes the merger agree
Slide 5: No Offer or Solicitation
5 No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction in connection
Slide 6: Combined Company – Investment Opportunity
6 Combined Company – Investment Opportunity Experienced management team and board of directors with track record of success and value creation Premier biologics company with vaccine and antibody expertise and a focus on infectious diseases and oncology Four clinical programs and multiple partnered p
Slide 7: Flu Antibody: TCN-032
7 Flu Antibody: TCN - 032 • IgG mAb that binds to a novel, highly - conserved universal epitope – Influenza A (H1N1; H5N1; H7N9) • Annually, 200,000 U.S. patients are hospitalized; 36,000 die from serious influenza infections* • Government stockpile market offers significant upside potential • Phase
Slide 8: TCN-032/Tamiflu Combination in Mice Lethal Challenge
8 TCN - 032 /Tamiflu Combination in Mice Lethal Challenge Protective Even When Treatment is Started 4 Days After Infection Day 4,6,8 20x LD 50 Vn1203 Noah et.al., Southern Research Institute mAb at 20 mg/kg on day +4, 6, 8 Oseltamivir at 10 mg/kg bid on day 1 - 5
Slide 9: Viral Challenge Protocol: Study Design
9 Viral Challenge Protocol: Study Design • Double - blind, placebo - controlled, randomized study • Population – Normal healthy subjects; males or females, age 18 - 45 years – Seronegative (HAI titer ≤ 10) to H3N2 challenge strain (A/Wisconsin/67/05) • Treatment: TCN - 032 40 mg/kg or placebo, given
Slide 10: Clinical Symptoms
10 Clinical Symptoms Clinical Symptoms TCN - 032 n=24 Placebo n=24 % Difference p value (one - sided) Proportion of subjects with grade 2 symptoms or pyrexia 10/24=41.2% 13/24=54.2% 12.5% p=0.21 CMH test AUC (Day 1 - 7) median 25.5 39 35% p=0.0466* Wilcoxon
Slide 11: Clinical Symptoms and Viral Shedding by PCR
11 Clinical Symptoms and Viral Shedding by PCR Clinical symptoms and viral shedding in both treatment arms follow similar patterns
Slide 12: Viral Shedding and Viral Escape Analysis
12 Viral Shedding and Viral Escape Analysis TCN - 032 AUC (log 10 TCID 50 /mL) Placebo AUC (log 10 TCID 50 /mL) Absolute Log Decrease p value (one - sided) PCR Day 2 - 7 Median=5.2 Median=7.4 2.2 p=0.09* Wilcoxon Viral escape genotypic analysis ▪ Sequence analysis (454 Next Generation) TCN - 032 epi
Slide 13: TCN-032: Phase 2a Human Viral Challenge Study
13 TCN - 032: Phase 2a Human Viral Challenge Study • Demonstrated reductions in total clinical symptom scores and viral load • Safe and well - tolerated with no increase in adverse events compared to placebo, including lower respiratory tract symptoms • Pharmacokinetics consistent with Phase 1 study
Slide 14: Cytomegalovirus (CMV) Antibody: TCN-202
14 Cytomegalovirus (CMV) Antibody: TCN - 202 • Recognizes broadly conserved epitope on CMV • Neutralizes CMV viral infection in many cell types – Epithelia, endothelial, fibroblasts, etc. • ~1,000x more potent than plasma - derived CMV - IGIV (preclinical studies)* • Phase 1 completed; favorable saf
Slide 15: TCN-202 Inhibits Cell to Cell Spread of HCMV
15 0.1 1 10 100 1000 0 200 400 600 800 1000 1200 Concentration (g/mL) Mean Plaque Size (pixels) TCN-202 Negative Control Mab TCN - 202 Inhibits Cell to Cell Spread of HCMV in Dermal Fibroblast Cultures TCN - 202 blocks both initial penetration and cell - to - cell spread of HCMV which may be import
Slide 16: TCN-202 Preclinical Studies of CMV Infected Decidual Tissue
16 TCN - 202 Preclinical Studies of CMV Infected Decidual Tissue Decidual Organ Cultures: D. Wolf (Hadassah University Hospital, Jerusalem) • Decidual tissue (1 st trimester pregnancy termination) • Pre - treatment of virus with mAb • Monitor HCMV replication via yellow fluorescent protein (YFP ) ex
Slide 17: TCN-202: Clinical Study Summary and Plans
17 TCN - 202: Clinical Study Summary and Plans Phase 1 completed 2Q 2013 • Well - tolerated in single doses of 1 - 50 mg/kg and multiple doses at 15 mg/kg x2 • AEs were mild to moderate; most were unrelated to study drug • Pharmacokinetics – Dose proportional ( Cmax and AUC) – Half - life ~14 days –
Slide 18: I-STAR: Generating Highly-Specific Human Antibodies
18 I - STAR ™ Generating Highly - Specific Human Antibodies for Significant Unmet Medical Needs Selected donor population convalescent/vaccinated subjects = protective Abs Superior B - cell activation Deep sequencing of all hit wells Rapid screen for binding and function IgG+ Memory B - cells “Archi
Slide 19: I-STAR Validating Partnerships
19 I - STAR TM Validating Partnerships January 2011 I - STAR™ collaboration to discover antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. Pfizer has Worldwide licensing rights. February 2008 IAVI collaboration to discover HIV - neutralizing antibodies M
Slide 20: Combined Company Executive Team
20 Combined Company Executive Team Clifford J. Stocks Chief Executive Officer Calistoga Pharmaceuticals, Inc., ICOS Corporation Francesca Cook SVP, Policy and Government Affairs Guilford Pharmaceuticals Covance Health Econ., U.S. HHS Russ Hawkinson Chief Financial Officer Corixa Corporation Ernst &
Slide 21: Combined Company Board of Directors
21 Combined Company Board of Directors Mitch Sayare, Ph.D. Chairman ImmunoGen XenoGen John M. Gill Tetralogic Pharmaceuticals 3D Pharma, SKB Steve Gillis, Ph.D. Immunex, Corixa, ARCH Venture Partners Wende Hutton Canaan Partners Mayfield Fund, GenPharma International Brian Markison King Pharmaceutic
Slide 22: Near-Term Valuation Catalysts
22 Near - Term Valuation Catalysts Presented CMV Antibody Phase 1 results Q3 13 Initiated CMV Antibody Phase 2a Q3 13 Presented Flu Antibody Phase 2a results Q3 13 Anticipate CMV Antibody Phase 2a results Q3 14 Event* Date *The Milestones listed above are targets established by PharmAthene and Thera
Slide 23: Turning the Repertoire's Most Potent Antibodies into Superior Therapeutics
Turning the Repertoire’s Most Potent Antibodies into Superior Therapeutics 1124 Columbia Street, Suite 300 Seattle, WA 98104 www.theraclone - sciences.com